These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 31445112)

  • 41. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.
    Connery HS
    Harv Rev Psychiatry; 2015; 23(2):63-75. PubMed ID: 25747920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 43. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between choice of opioid agonist therapy and distance from patients' residences in Taiwan, 2012-2014.
    Wei LC; Chan HY
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):590-598. PubMed ID: 34402338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder.
    McKendrick G; Stull SW; Sharma A; Dunn KE
    Semin Neurol; 2024 Aug; 44(4):419-429. PubMed ID: 38876459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A mixed-methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community-based care in England and Wales.
    Gibson R; MacLeod N; Donaldson LJ; Williams H; Hibbert P; Parry G; Bhatt J; Sheikh A; Carson-Stevens A
    Addiction; 2020 Nov; 115(11):2066-2076. PubMed ID: 32149443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
    Holbrook AM
    Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Buprenorphine and methadone for opioid addiction during pregnancy.
    Mozurkewich EL; Rayburn WF
    Obstet Gynecol Clin North Am; 2014 Jun; 41(2):241-53. PubMed ID: 24845488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 52. Diagnosis and Treatment of Opioid Use Disorder in 2020.
    Wakeman SE
    JAMA; 2020 May; 323(20):2082-2083. PubMed ID: 32329798
    [No Abstract]   [Full Text] [Related]  

  • 53. CE: Acute Pain Management for People with Opioid Use Disorder.
    Broglio K; Matzo M
    Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Opioid Use Disorder and Incarceration - Hope for Ensuring the Continuity of Treatment.
    Binswanger IA
    N Engl J Med; 2019 Mar; 380(13):1193-1195. PubMed ID: 30811904
    [No Abstract]   [Full Text] [Related]  

  • 55. Using buprenorphine to treat patients with opioid use disorder.
    Radi JK; Fogarty KJ; Lagerwey MD
    JAAPA; 2019 Oct; 32(10):30-35. PubMed ID: 31513035
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
    Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
    Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
    Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
    Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Buprenorphine Maintenance vs. Placebo for Opioid Dependence.
    Raleigh MF
    Am Fam Physician; 2017 Mar; 95(5):Online. PubMed ID: 28290640
    [No Abstract]   [Full Text] [Related]  

  • 59. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
    Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
    J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Within-subject evaluation of interim buprenorphine treatment during waitlist delays.
    Oleskowicz TN; Ochalek TA; Peck KR; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2021 Mar; 220():108532. PubMed ID: 33508690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.